CD274 and non-small cell lung carcinoma: First, only two RCTs that investigated the efficacy and safety of anti‐PD‐1/PD‐L1 antibodies for patients with previously untreated advanced NSCLC were available for inclusion, which limited the number of studies available for our meta‐analyses.